Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Chris Hartz to Helm Amicus Japan
October 8, 2019
- Japan Ethical Drug Sales Up 3.0% in August: Crecon
October 8, 2019
- Keytruda Filed for Gastric Cancer in Japan
October 7, 2019
- Keytruda Remains Japan’s Top-Selling Drug in September: Encise
October 7, 2019
- Shionogi, M3 Establish New JV to Provide Disease Solutions by Integrating Physical and Digital Assets
October 7, 2019
- Trader Mitsui’s Iwai Picked for Top Job at Fuji Pharma
October 7, 2019
- All 11 Manufacturers Pull Ranitidine from Shelves, “Class I” Recalls for 9 Firms
October 4, 2019
- Japan IP High Court Favors Chugai in Hemlibra Patent Suit
October 4, 2019
- Novel Antibiotic Cefiderocol Meets Primary Endpoint in Global PIII: Shionogi
October 4, 2019
- Kissei to Leverage Its Track Record with EPO to Promote Nesp Biosimilar: President
October 4, 2019
- Novo Nordisk Poised to Cash in on New GLP-1 Agents to Hit 100 Billion Yen Japan Sales
October 3, 2019
- SymBio Bags Global Rights to Antiviral Brincidofovir from US Biotech, Aiming to Become Hematology Specialty Pharma
October 3, 2019
- Astellas to Make US$13 Million Investment in Boston Area to Support Startups
October 3, 2019
- Health Canada Accepts Mitsubishi Tanabe’s Plant-Derived Flu Vaccine for Review
October 3, 2019
- Nippon Shinyaku Seeks US Approval for DMD Therapy Viltolarsen
October 3, 2019
- Asahi Kasei Sues Endo over Xiaflex Supply Halt
October 2, 2019
- Axcelead Gets Its Hands on PassPort’s Transdermal Drug Delivery Technology
October 2, 2019
- Taisho Grabs Japan Rights to Moberg’s Topical Onychomycosis Drug
October 2, 2019
- Nippon Zoki to Develop Its 1st Biologic by Licensing Bone Forming Promoting Drug from South Korean Biotech
October 2, 2019
- Eisai, US Merck Present Final PII Results for Lenvima/Keytruda Combo for Endometrial Cancer
October 2, 2019
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…